Obsessive-compulsive disorder in schizophrenia: Epidemiologic and biologic overlap

Journal of Psychiatry and Neuroscience

Volumn 24, Issue 1, 1999, Pages 15-24

  Tibbo, Philip ^a,c   Warneke, Lorne ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b GREY NUNS COMMUNITY HOSPITAL   (Canada)

^c UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

Comorbidity; Dopamine; Epidemiology; Obsessive compulsive disorder; Prefrontal cortex; Receptors, dopamine; Receptors, serotonin; Schizophrenia; Serotonin; Thalamus

Indexed keywords

CLOTIAPINE; CLOZAPINE; DOPAMINE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; RISPERIDONE; SEROTONIN;

COMORBIDITY; DRUG INDUCED DISEASE; HUMAN; OBSESSION; PREVALENCE; REVIEW; SCHIZOPHRENIA;

BRAIN; COMORBIDITY; HUMANS; NEUROTRANSMITTER AGENTS; OBSESSIVE-COMPULSIVE DISORDER; SCHIZOPHRENIA;

EID: 0032972847     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Berrios GE. Obsessive-compulsive disorder: its conceptual history in France during the 19th century. Compr Psychiatry 1989;30:283-95.
2. Jahrrheis W. Obsessions during schizophrenia. Arch Psych Nervenk 1926;77:740-788.
3. Stengel E. A study of some clinical aspects of the relationship between obsessional neurosis and psychotic reaction types. J Ment Sci 1945;41:166-87.
4. Gordan A. Transition of obsessions into delusions:evaluation of obsessional phenomena from a prognostic standpoint. Am J Psychiatry 1950;107:455-8.
5. Rosen I. The clinical significance of obsessions in schizophrenia. J Ment Sci 1957;103:773-85.
6. Parkin A. Neurosis and schizophrenia: II. Modern perspectives. Psychiatry Q 1966;40:217-35.
7. Bernie WA, Litman SK. Obsessionality in schizophrenia. Can Psychiatr Assoc J 1978;23:77-81.
8. Fenton WS, McGlashan TH. The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry 1986;143:437-41.
9. Berman I, Kalinowski A, Berman SM, Lengua J, Green AI. Obsessive and compulsive symptoms in chronic schizophrenia. Compr Psychiatry 1995;36:6-10.
10. Eisen JL, Beer DA, Pato MT, Venditto TA, Rasmussen SA. Obsessive-compulsive disorder in patients with schizophrenia or schizoaffective disorder. Am J Psychiatry 1997;154:271-3.
11. Fabisch K, Fabisch H, Langs G, Wieselmann G, Zapotoczky HG. Obsessive-compulsive symptoms in schizophrenia. Schizophr Res 1997;24:17.
12. Porto L, Bermanzohn P, Siris S, Pollack S, Morrisey R. A profile of obsessive compulsive symptoms in schizophrenia. Schizophr Res 1997;24:20.
13. Pollit JD. Natural history of obsessional states. BMJ 1957;1:194-8.
14. Kringlen E. Obsessional neurotics: a long-term follow up. Br J Psychiatry 1965;111:709-22.
15. Lo W. A follow-up study of obsessional neurotics in Hong Kong Chinese. Br J Psychiatry 1967;113:823-32.
16. Rosenberg CM. Complications of obsessional neurosis. Br J Psychiatry 1968;114:477-8.
17. Welner A, Reich T, Robins E, Fishman R, Van Doren T. Obsessive compulsive neurosis: record, follow-up and family studies. Compr Psychiatry 1976;17:527-39.
18. Eisen JL, Rasmussen SA. Obsessive-compulsive disorder with psychotic features. J Clin Psychiatry 1993;54:373-9.
19. Thomsen PH, Jensen J. Obsessive-compulsive disorder: admission patterns and diagnostic stability. A case-register study. Acta Psychiatr Scand 1994;90:19-24.
20. Karno M, Golding JM, Sorensen SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988;45:1094-9.
21. Bland RC, Newman SC, Orn H. Schizophrenia: lifetime comorbidity in a community sample. Acta Psychiatr Scand 1987; 75:383-91.
22. Lewis A. Problems of obsessional illness. Prof R Soc Med 1936;29:325-35.
23. Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol 1993;50:873-80.
24. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990;13:266-71.
25. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-81.
26. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 1990;85: 119-46.
27. Groenewegen HJ, Berendse HW, Wolters JG, Lohman AH. The anatomical relationship of the prefrontal cortex with the stiatopallidal system, the thalamus and the amygdala: evidence for a parallel organization. Prog Brain Res 1990;85:95-116.
28. Parent A. Extrinsic connections of the basal ganglia. Trends Neurosci 1990;13:254-8.
29. Modell SC, Mountz JM, Curtis GC, Greden JF. Neurophysiologic dysfunction in basal ganglia/limbic striatal and thalamocortical circuits as a pathogenetic mechanism of obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 1989;1:27-36.
30. Chiocca EA, Martuza RI. Neurosurgical therapy of the obsessive-compulsive disorder. In: Jeneke MA, Baer L, Minichiello WE (editors). Obsessive-compulsive disorders: theory and management. 2nd ed. Chigago (IL): Mosby Yearbook Medical; 1990. p. 283-4.
31. Talairach J, Bancaud J, Geier S, Bordas-Ferrer M, Bonis A, Szikla G, et al. The cingulate gyrus and human behavior. Electroencephalogr Clin Neurophysiol 1973;34:45-52.
32. Mindus P, Jenike MA. Neurosurgical treatment of malignant obsessive compulsive disorder. Psychiatr Clin North Am 1992;15:921-38.
33. Baxter LR, Schwartz JM, Bergman KS, Szuka MP, Guze BH, Mazziotta JC, et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49:681-9.
34. Luxenberg JS, Swedo SE, Flament MF, Friedland RP, Rapoport JL, Rapoport SI. Neuroanatomical abnormalities in obsessive-compulsive disorder detected with quantitative X-ray computed tomography. Am J Psychiatry 1988;145:1089-1093.
35. Kellner CH, Jolley RR, Holgate RC, Augstin L, Lydiard RB, Laraia M, et al. Brain MRI in obsessive-compulsive disorder. Psychiatry Res 1991;36:45-9.
36. Weilburg JB, Mesulam MM, Weintraub S, Buonannon F, Jenike M, Stakes JW. Focal striatal abnormalities in a patient with obsessive-compulsive disorder. Arch Neurol 1989;46:233-5.
37. Baxter LR, Phelps ME, Mazziotta SC, Guze BH, Schwartz JM, Selin CE. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Arch Gen Psychiatry 1987;44:211-8.
38. Baxter LR. PET studies of cerebral function in major depression and obsessive-compulsive disorder: the emerging prefrontal cotex consensus. Ann Clin Psychiatry 1991;3:103-9.
39. Martinot JL, Allilaire JF, Mazoyer BM, Hantouche E, Huret JD, Legault-Demare F, et al. Obsessive-compulsive disorder: a clinical, neuropsychological and positron emission tomography study. Acta Psychiatr Scand 1990;82:233-42.
40. Adams BL, Warneke LB, McEwan MB, Fraser BA. Single photon computerized tomography in obsessive compulsive disorder: a preliminary study. J Psychiatr Neurosci 1993;18:109-12.
41. Rauch SL, Jenike MA, Alpert NM, Baer L, Breiter HCR, Savage CR, Fischman AJ. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 1994;51:62-70.
42. Swedo SE, Pietrini P, Leonard HL, Schapiro MB, Rettew DC, Goldberger EL, et al. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder: revisualization during pharmacotherapy. Arch Gen Psychiatry 1992;49:690-4.
43. Rapoport JL, Wise SP. Obsessive-compulsive disorder: Evidence for basal ganglia dysfunction. Psychopharmacol Bull 1988;24:380-4.
44. Deymeer F, Smith TW, DeGirolami U, Drachman DA. Thalamic dementia and motor neuron disease. Neurology 1989;39:58-61.
45. Moossy J, Martinez J, Hanin I, Rao G, Yonas H, Boller F. Thalamic and subcortical gliosis with dementia. Arch Neurol 1987;44:510-513.
46. Haut MW, Cahill J, Cutlip WD, Stevenson JM, Makela EH, Bloomfield SM. On the nature of WCST performance in schizophrenia. Psychiatry Res 1996;65(1):15-22.
47. Stanley JA, Williamson PC, Drost DJ, Carr TJ, Rylett RJ, Maller A, et al. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry 1995; 52(5):399-406.
48. Seidman LJ, Yurgelum-Todd D, Kremon WS, Woods BT, Goldstein JM, Faraone SW, et al. Relationship of prefrontal and temporal lobe MRI measures to neuropsychological performance in chronic schizophrenia. Biol Psychiatry 1994; 35(4):235-46.
49. Andreasen NC, Ehrhardt JC, Swayze VW, Alliger R, Yuh WTC, Cohen G, et al. Magnetic resonence imaging of the brain in schizophrenia: the pathophysiological significance of atructural abnormalities. Arch Gen Psychiatry 1990;47:35-44.
50. Andreasen NC, Arndt S, Swayze V, Cizaldo T, Flaum M, O'Leary D, et al. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 1994;266:294-8.
51. Flaum M, Swayze VWII, O'Leary DS, Yuh WTC, Erhardt JC, Arndt S, et al. Effects of diagnosis,laterality,and gender on brain morphology in schizophrenia. Am J Psychiatry 1995; 152:704-14.
52. Bauchsbaum MS, Haier RJ, Potkin SG, Neuchterlain K, Brach HS, Katz M, et al. Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics. Arch Gen Psychiatry 1992;49:935-42.
53. Andreasen NC. The role of the thalamus in schizophrenia. Can J Psychiatry 1997;42:27-33.
54. Molliver M. Serotonergic neuronal systems: what their anatomic organisation tells us about their function. J Clin Psychopharmacol 1987;7:3S-23S.
55. 1 receptor agonists and p-chloroamphetamine. Synapse 1990;5:120-33.
56. Audet MA, Descarries L, Doucet G. Quantified regional and laminar distribution of the serotonin innervation in the anterior half of adult rat cerebral cortex. J Chem Neuroanat 1989; 2:29-44.
57. Grimsley SR, Jann MW. Paroxetine,sertraline,and fluvoxamine: New selective serotonin reuptake inhibitors. Clin Pharmacol 1992;11:930-57.
58. Cowen PJ, Charig EM. Neuroendocrine responses to tryptophan in major depression. Arch Gen Psychiatry 1987;44:958-66.
59. 2 recognition sites. Brain Res 1986;376:97-107.
60. 2 receptor sensitivity after continuous gepirone treatment. Eur J Pharmacol 1985;389-92.
61. Glennon RA, Darmani NA, Martin BR. Multiple populations of serotonin receptors may modulate the behavioral effects of serotonergic agents. Life Sci 1991;48;2493-8.
62. 1A receptors. Br J Pharmacol 1990;100:793-9.
63. 2 agonist DOI. Eur J Pharmacol 1989;161:45-51.
64. Olpe HR, Koella WP. The response of striatal cells upon stimulation of the dorsal and median raphe nuclei. Brain Res 1977; 122:357-60.
65. Dewey SL, Smith GS, Logan J, Alexoff D, Ding YS, King P, et al. Serotonergic modulation of striatal dopamine measured with positron emmision tomography (PET) and in vivo microdialysis. J Neurosci 1995;15:821-9.
66. Pittman RK, Green RC, Jenike MA, Mesulam MM. Clinical comparison of Tourette's disorder and obsessive-compulsive disorder. Am J Psychiatry 1989;144:1166-71.
67. Laird LK. Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder. Psychopharmacol Bull 1996;32(4):569-78.
68. Saxena S, Wang D, Poystritsky A, Baxter L. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303-6.
69. Goodman WK, McDougle CJ, Price LH. The role of serotonin and dopamine in the pathophysiology of obsessive compulsive disorder. Intern Clin Psychopharmacol 1992;7(Suppl 1):35-8.
70. Ghaemi SN, Zarate CA, Popli AP, Pillay SS, Cole JO. Is there a relationship between clozapine and obsessive-compulsive disorder? A retrospective chart review. Compr Psychiatry 1995; 36:267-70.
71. Mozes T, Toren P, Chemauzan N, Mester R, Yoran-Hegesh R, Blumensohn R, et al. Clozapine treatment in very early onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1994;33:65-70.
72. Buckley PF, Sajatovic M, Meltzer HY. Treatment of delusional disorders with clozapine. Am J Psychiatry 1994;151:1394-5.
73. Eales MJ, Layeni AO. Exacerbation of obsessive-compulsive symptoms associated with clozapine. Br J Psychiatry 1994; 164:687-8.
74. Patil VJ. Development of transient obsessive-compulsive symptoms during treatment with clozapine. Am J Psychiatry 1992;149-272.
75. Levkovich Y, Kronnenberg Y, Gaoni B. Can clozapine trigger OCD. J Am Acad Child Adolesc Psychiatry 1995;34:263.
76. Patel B, Tandon R. Development of obsessive-compulsive symptoms during clozapine treatment. Am J Psychiatry 1993; 150:836.
77. Allen L. Tejera C. Treatment of clozapine induced obsessive-compulsive symptoms with sertraline. Am J Psychiatry 1994; 151:1096-7.
78. Cassady SL, Thaker GK. Addition of fluoxetine to clozapine. Am J Psychiatry 1992;149:1274.
79. Baker RW, Chengappa KNR, Baird JW, Steingard S, Christ MAG, Schooler NR. Emergence of obsessive compulsive sumptoms during treatment with clozapine. J Clin Psychiatry 1992;53:439-42.
80. Remington G, Adams M. Risperidone and obsessive-compulsive symptoms. J Clin Psychopharmacol 1994;14:358-9.
81. Kopala L, Honer WG. Risperidone, serotonergic mechanisms, and obsessive compulsive symptoms in schizophrenia. Am J Psychiatry 1994;151:1714-5.
82. Alzaid K, Jones BD. A case of risperidone induced obsessive-compulsive symptoms. J Clin Psychopharmacol 1997;17:58-9.
83. Dodt JE, Byerly MJ, Cuadros C, Christensen RC. Treatment of risperidone-induced obsessive-compulsive symptoms with sertraline. Am J Psychiatry 1997;154(4):582.
84. Toren P, Samuel E, Weizman R, Golomb A, Eldar S, Laor N. Emergence of transient compulsive symptoms during treatment with clothiapine. J Am Acad Child Adolesc Psychiatry 1995;34:1469-72.
85. Baker RW, Ames D, Umbricht DSG, Chengappa R, Schooler NR. Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo. Psychopharmacol Bull 1996;32(1):89-93.
86. 2 receptors. Psychopharmacology (Berl) 1993;112:S40-S54.
87. Dursum SM, Reveley MA. Obsessive-compulsive symptoms and clozapine. Br J Psychiatry 1994;165:267-8.
88. Abi-Dargham A, Laruelle M, Aghajanian GK, Charney D, Krystal J. The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatry Clin Neurosci 1997;9:1-17.
89. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischman-Hill CL, Heninger GR, et al. The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-11.
90. Dominquez RA, Jacobson AF, de la Gandera J. Drug rcesponse assessed by the Modified Maudsley Obsessive Compulsive Inventory. Psychopharmacol Bull 1989;25:215-8.